First report of post-transplant autoimmune hepatitis recurrence following SARS-CoV-2 mRNA vaccination

Whilst vaccination for the SARS-CoV-2 virus has been successful in reducing the severity and burden of the COVID-19 pandemic, there have been recent reports of mRNA vaccines triggering autoimmune hepatitis in the native liver. There have been no descriptions thus far of recurrent ‘autoimmune hepatit...

Descripción completa

Detalles Bibliográficos
Autores principales: Mahalingham, Aarani, Duckworth, Adam, Griffiths, William J.H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Published by Elsevier B.V. 2022
Materias:
Brief Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8977213/
https://www.ncbi.nlm.nih.gov/pubmed/35390478
http://dx.doi.org/10.1016/j.trim.2022.101600
Descripción
Sumario:Whilst vaccination for the SARS-CoV-2 virus has been successful in reducing the severity and burden of the COVID-19 pandemic, there have been recent reports of mRNA vaccines triggering autoimmune hepatitis in the native liver. There have been no descriptions thus far of recurrent ‘autoimmune hepatitis’ after liver transplantation in the context of SARS-CoV-2 vaccination. We describe a patient transplanted for autoimmune hepatitis who was stable for many years until they had immune-mediated flares coinciding with Pfizer-BioNTech mRNA vaccination. Intravenous steroid treatment was required to suppress histologically evident interface hepatitis. We firmly believe that mRNA vaccination was responsible for this ‘recurrence’ and that clinicians should be vigilant for this reaction in patients transplanted for autoimmune hepatitis.

Ejemplares similares